Welcome to our dedicated page for N2OFF news (Ticker: NITO), a resource for investors and traders seeking the latest updates and insights on N2OFF stock.
N2OFF, Inc. (NASDAQ: NITO) generates news across several distinct areas, reflecting its profile as a clean tech and cleantech company with activities in renewable energy, agri-tech, and biotechnology. Company announcements describe N2OFF as mainly engaged in EU-based solar assets using a Ready to Build (RTB) business model, while also owning MitoCareX Bio Ltd., a drug discovery company targeting cancer therapeutics through the mitochondrial SLC25 protein family, and controlling a majority stake in Save Foods Ltd., an Israeli post-harvest treatment company focused on pathogen contamination in fruits and vegetables.
News updates frequently cover renewable energy milestones, including progress on solar photovoltaic and battery energy storage projects in European Union countries through partnerships with Solterra Renewable Energy Ltd. These releases highlight permitting developments, funding arrangements, and changes in project economics for flagship projects in markets such as Germany and Italy.
Another stream of coverage focuses on biotech and precision oncology activity at MitoCareX. N2OFF reports on scientific advances related to mitochondrial SLC25 transport proteins, the use of the MITOLINE™ algorithm for 3D protein modeling and virtual screening, and progress toward identifying hit compounds and potential preclinical candidates for hard-to-treat cancers.
Investors following NITO news will also see corporate and capital markets updates, such as the completion of the MitoCareX acquisition, reverse stock split implementation, Nasdaq minimum bid price compliance, and agreements involving the planned transfer of N2OFF’s majority stake in Save Foods to Voice Assist, Inc. Together, these categories of news provide insight into how N2OFF manages its multi-segment portfolio across clean energy, agri-tech, and biotech drug discovery.
N2OFF (NASDAQ: NITO) subsidiary MitoCareX Bio reported Feb 12, 2026 in‑vitro data showing MITOLINE™‑powered small molecules reduced pro‑inflammatory markers in human immune cells. The results support further in vivo validation and lead optimization for metabolic syndrome‑related inflammatory indications and expansion of MITOLINE™ discovery programs.
N2OFF (NASDAQ: NITO) highlighted a peer‑reviewed study co‑authored by Prof. Ciro Leonardo Pierri on SLC25A mitochondrial carriers as biomarkers and therapeutic targets for spaceflight‑induced dysfunction. The December 30, 2025 Journal of Translational Medicine article examined 53 SLC25A genes and used AAC3 as a structural case study.
The research aligns with MitoCareX Bio's focus and its MITOLINE™ platform for virtual modeling and small‑molecule discovery targeting mitochondrial carriers.
N2OFF (NASDAQ: NITO) subsidiary MitoCareX Bio reported preliminary in vitro data (Jan 22, 2026) showing selected MITOLINE™‑derived small‑molecule candidates reduce key pro‑inflammatory markers in human immune cells. The results support further in vivo validation and lead optimization across inflammatory metabolic disease indications. MITOLINE™ creates 3D comparative models of mitochondrial carriers to enable virtual screening. Management plans to advance lead candidates toward pre‑clinical studies.
N2OFF (NASDAQ: NITO) highlighted a peer‑reviewed study co‑authored by Prof. Ciro Leonardo Pierri on SLC25A mitochondrial carriers as biomarkers and therapeutic targets for spaceflight‑induced dysfunction. Published online Dec 30, 2025 (DOI: 10.1186/s12967-025-07505-z), the study analyzed expression of 53 SLC25A genes across osteocytes, hBMSCs, and mouse brain exposed to microgravity and space stressors, and used AAC3 (ADP/ATP carrier) as a structural case study. The research aligns with MitoCareX Bio's focus and its MITOLINE™ computational platform for screening small‑molecule modulators of SLC25A carriers.
N2OFF (NASDAQ: NITO) advanced its European solar portfolio via partner Solterra by providing a $340,000 advance to secure improved development economics and monetization optionality.
As part of an amendment, Solterra accepted a €11,000 per MW reduction in development fees that N2OFF says increases potential project profit by approximately $1.7 million. N2OFF's flagship German project is on track for Q3 2026 approval, with the draft zoning plan due for final consultation in late January 2026 and multiple value-realization pathways expected beginning in H2 2026.
N2OFF (NASDAQ: NITO) reported de-risking progress and a value unlock across European projects in partnership with Solterra Renewable Energy. Key outcomes include zero objections in Germany's public consultation, formal planning submissions in Italy, and an estimated $1.69 million of project-level savings realized through a capital-efficient amendment.
The German flagship aims for final approval in Q3 2026; Solterra received ~€280,000 advance funding in exchange for a €11,000 per MW reduction in development fees. Sicilian battery projects have binding grid capacity, preliminary land agreements and target planning approvals in H2 2026, after which N2OFF will decide sale versus build-and-operate.
N2OFF (NASDAQ: NITO) completed the acquisition of MitoCareX and published a shareholder letter outlining MitoCareX’s strategy, milestones, and pipeline powered by its proprietary MITOLINE™ algorithm.
MitoCareX reports it has identified promising hit compounds with measurable biological activity against a mitochondrial SLC25 transport protein linked to aggressive cancers, and plans hit-to-lead optimization, PK profiling, and nomination of a preclinical development candidate in 2026. Management is pursuing licensing and collaborations to generate non-dilutive revenue and aims to prepare for IND-enabling studies while positioning MITOLINE™ as a scalable discovery engine.
N2OFF (NASDAQ: NITO) completed its acquisition of MitoCareX on October 20, 2025, making MitoCareX a wholly owned subsidiary following satisfaction of closing conditions under a February 25, 2025 securities purchase and exchange agreement.
Transaction details include a $700,000 cash purchase of shares from SciSparc, issuance of N2OFF common stock representing 40% of fully diluted capital to MitoCareX sellers, seller rights to 30% of financing proceeds (capped at $1.6M) for five years, and milestone-based issuances up to 25% of common stock. N2OFF committed to fund MitoCareX operations for the first two post-close years. MitoCareX focuses on mitochondrial SLC25 targets and a computational platform called MITOLINE for small-molecule discovery in hard-to-treat cancers.
N2OFF (NASDAQ: NITO) closed its acquisition of MitoCareX on October 20, 2025, making MitoCareX a wholly owned subsidiary focused on drug discovery targeting mitochondrial SLC25 proteins and hard-to-treat cancers including pancreatic and non-small cell lung cancer.
N2OFF paid $700,000 to SciSparc for MitoCareX shares and issued N2OFF common stock representing 40% of fully diluted capital to the sellers. Sellers are entitled to 30% of financing proceeds (capped at $1.6M) for five years and up to 25% additional common stock
N2OFF (NASDAQ: NITO) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq confirmed on October 6, 2025 that N2OFF's American Depositary Shares closed at $1.00 or greater for 10 consecutive business days (September 22, 2025 to October 3, 2025), closing the prior deficiency. The company had been notified of non-compliance on March 28, 2025 after ADSs traded below $1.00 for more than 30 consecutive business days. N2OFF is a cleantech investor using the RTB (Ready to Build) model, lead investor in four EU solar projects across three countries, and controls ~98% of Save Foods, a post-harvest treatments company.